New Stock News | Guangdong Hec Technology Holding Medicine (06887) Completes Innovative Capital Operation on Hong Kong Stock Exchange Main Board and Will Land on August 7

On July 29th, HEC CJ PHARM completed its last trading day, officially launching the first "H-share privatization through absorption and merger + introduction to listing" innovative capital operation in the Hong Kong stock market. According to the plan, the company will debut on the Hong Kong Stock Exchange main board on August 7th with "Guangdong Hec Technology Holding Medicine" (06887) as the main entity, pioneering a new paradigm of asset securitization for Chinese innovative pharmaceutical enterprises. Guangdong Hec Technology Holding Medicine will absorb and merge its subsidiary HEC CJ PHARM, which is listed on the Hong Kong Stock Exchange. This means that the main entity seeking listing, Guangdong Hec Technology Holding Medicine, will apply for an H-share listing and issue H shares to minority shareholders of its subsidiary HEC CJ PHARM in exchange for their shares. After the absorption and merger is completed, Guangdong Hec Technology Holding Medicine will go public through an introduction. Industry insiders point out that this move not only breaks down the time barrier of traditional capital operations, reduces the friction cost of capital generated in mergers and acquisitions, integrates resources and upgrades capital, but also effectively safeguards shareholder rights. It provides a replicable example for industry integration and international development, and is a vivid demonstration of positive response to the national decision to "optimize the capital market structure." The person in charge of Guangdong Hec Technology Holding Medicine stated that after listing in Hong Kong, the company will receive long-term capital support and is expected to achieve industrial upgrading through integrated driving. This means that the research and development capabilities and pipeline of Guangdong Hec Technology Holding Medicine will join forces with the nationwide sales network of HEC CJ PHARM to create a "research and development - production - sales" loop, and build a global operating platform. According to the information, Guangdong Hec Technology Holding Medicine is a comprehensive pharmaceutical company engaged in the research, production, and commercialization of drugs, focusing on innovative drugs including improved new drugs, generic drugs, and biosimilars. Adhering to innovation, internationalization, and sustainability, the company is driven by independent research and development, strategically focusing on therapeutic areas such as infections, chronic diseases, and tumors. It already has a mature and benign business model and is striving towards the goal of becoming a world-class innovative pharmaceutical enterprise. This article is reprinted from "Securities Times Network" by Zhang Xiexin; GMTEight editor: Xu Wenqiang.